NEW YORK (GenomeWeb News) — Vermillion has licensed a biomarker panel from Stanford University that could be used to assess the risk of peripheral artery disease, the company said today.
 
The agreement gives Vermillion exclusive rights to develop and commercialize a blood-based PAD test, which would use the multi-marker panel to stratify individual risk for developing the disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.